secwatch.observer — SEC 8-K summary
======================================

Issuer:     G1 Therapeutics, Inc. (—)
CIK:        0001560241
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001628280-24-019453
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

G1 Therapeutics Q1 2024: COSELA revenue $14.1M, net loss $10.2M, reaffirms 2024 guidance
--------------------------------------------------------------------------------

- Net COSELA revenue $14.1M in Q1 2024; total revenue $14.5M, up from $12.9M YoY.
- Net loss $10.2M ($0.20 per share) vs $27.6M ($0.53) in Q1 2023.
- Cash and securities $65.2M; runway into Q3 2025.
- Reaffirmed FY2024 COSELA net revenue guidance of $60-70M.
- Phase 3 PRESERVE 2 final analysis expected late Q2 2024; Phase 2 trilaciclib+ADC data at ASCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/0001628280-24-019453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1560241/000162828024019453/gthx-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-019453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer